Form 4: Baker Bros. Advisors Report Stock Option Grant in TScan Therapeutics

Baker Bros. Advisors LP reports the grant of non-qualified stock options to Dr. Stephen R. Biggar, a director of TScan Therapeutics, Inc., on June 12, 2024.

Summary

• Baker Bros. Advisors LP filed a Form 4 detailing changes in beneficial ownership of TScan Therapeutics, Inc. (TCRX) securities.
• The report concerns the grant of 47,500 non-qualified stock options to Dr. Stephen R. Biggar, an employee of Baker Bros. Advisors LP and a director of TScan Therapeutics.
• The options were granted on June 12, 2024, with an exercise price of $8.88 per share.
• The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, contingent on Dr. Biggar's continued service on the board.
• The options expire on June 11, 2034.
• The filing also clarifies the indirect beneficial ownership of these options by various Baker Bros. entities, including 667, L.P., Baker Brothers Life Sciences, L.P., and related individuals Julian C. Baker and Felix J. Baker.
• These entities disclaim direct beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral to positive as it incentivizes board members. The sentiment is slightly positive due to the alignment of interests.

Positives

• The grant of stock options to a director aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Industry Context

Stock options are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their board members.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the director to act in the best interests of the company, which could benefit all stakeholders.

Key Dates